{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:45:07Z","timestamp":1792161907813,"version":"4.4.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The aim of this study was to investigate the role of <jats:sup>18<\/jats:sup>F-fluciclovine PET\/CT in the evaluation of prostate cancer (PC) patients after definitive treatment in the presence of undetectable prostate-specific antigen (PSA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This retrospective study was conducted in PC patients who had undetectable PSA level and underwent fluciclovine PET\/CT within a 2-week interval of PSA examination and without interval treatment or other cancer. Patient and tumor characteristics at initial diagnosis, treatment regimens, and findings on fluciclovine PET\/CT were collected. Comparisons between groups of positive and negative fluciclovine PET\/CT were done by using descriptive statistics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 34 fluciclovine PET\/CTs from 34 patients met the inclusion criteria. There were 4 positive (11.8%) and 30 negative fluciclovine PET\/CTs (88.2%). All of the patients with positive results had an initial Gleason score of 7 or higher and locally advanced tumor (T3\u2013T4). More common features at the time of diagnosis among positive study patients as compared with negative ones were atypical histologic variants (25% vs 0%) and very high-risk PC (50% vs 30%). Most of the patients with positive study received second-line hormonal therapy (HT) (50%), whereas patients with negative results received first-line HT (53.3%). Chemotherapy naivety was less common among positive patients (75% vs 96.7%). Sites of involvement on positive fluciclovine PET\/CTs were pelvic lymph nodes (2\/4, 50%), lung and mediastinal lymph node (1\/4, 25%), and prostatectomy bed (1\/4, 25%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In the presence of undetectable PSA in PC patients after definitive treatment, fluciclovine PET\/CT would benefit most to patients with Gleason score of 7 or higher, high disease burden (T3\u2013T4), and atypical histologic variants at the time of diagnosis, and the ones who have history of second-line HT and\/or chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003122","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T21:21:27Z","timestamp":1601500887000},"page":"672-678","source":"Crossref","is-referenced-by-count":10,"title":["Is There Any Role for 18F-Fluciclovine PET\/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?"],"prefix":"10.1097","volume":"45","author":[{"given":"Ajalaya","family":"Teyateeti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiraya","family":"Teyateeti","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homer A.","family":"Macapinlac","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cncr.22372","article-title":"Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level","volume":"109","year":"2007","journal-title":"Cancer"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1464-410X.2003.04633.x","article-title":"Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia","volume":"93","year":"2004","journal-title":"BJU Int"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","year":"1999","journal-title":"JAMA"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1200\/JCO.2005.06.058","article-title":"Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib5-20230925","first-page":"254ra125","article-title":"Tumor clone dynamics in lethal prostate cancer","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00259-017-3723-3","article-title":"Therapy assessment in prostate cancer using choline and PSMA PET\/CT","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","year":"2014","journal-title":"Eur Urol"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","year":"2015","journal-title":"Cell"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"12448","DOI":"10.18632\/oncotarget.2558","article-title":"Early outcome prediction on 18F-fluorocholine PET\/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"5","year":"2014","journal-title":"Oncotarget"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/RLU.0000000000002310","article-title":"ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET\/CT for recurrent prostate cancer","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1097\/RLU.0000000000000849","article-title":"18F-Fluciclovine PET\/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00259-016-3383-8","article-title":"Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET\/CT: comparison with CT","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.juro.2016.09.117","article-title":"Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography\/computerized tomography imaging in the staging of biochemically recurrent prostate Cancer","volume":"197","year":"2017","journal-title":"J Urol"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/RLU.0000000000002432","article-title":"18F-Fluciclovine PET\/CT detection of recurrent prostate carcinoma in patients with serum PSA <\/= 1 ng\/mL after definitive primary treatment","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/MNM.0000000000001051","article-title":"Comparison of 18F-fluciclovine PET\/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer","volume":"40","year":"2019","journal-title":"Nucl Med Commun"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/RLU.0000000000002963","article-title":"Comparison of diagnostic utility of fluciclovine PET\/CT versus pelvic multiparametric MRI for prostate cancer in the pelvis in the setting of rising PSA after initial treatment","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00259-015-3177-4","article-title":"(11)C-Choline PET\/CT in castration-resistant prostate cancer patients treated with docetaxel","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13550-019-0554-1","article-title":"[68Ga]Ga-PSMA-11 PET\/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?","volume":"9","year":"2019","journal-title":"EJNMMI Res"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2217\/fon.15.277","article-title":"Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers","volume":"12","year":"2016","journal-title":"Future Oncol"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0022-5347(01)66713-2","article-title":"The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies","volume":"154","year":"1995","journal-title":"J Urol"},{"key":"bib23-20230925","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000020289","article-title":"Low PSA metastatic androgen-independent prostate cancer","volume":"38","year":"2000","journal-title":"Eur Urol"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3122\/jabfm.16.4.343","article-title":"Prostate cancer with a normal PSA: small cell carcinoma of the prostate\u2014a rare entity","volume":"16","year":"2003","journal-title":"J Am Board Fam Pract"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/00365599609182335","article-title":"Progression from adenocarcinoma to small cell carcinoma of the prostate with normalization of prostate-specific antigen (PSA) levels","volume":"30","year":"1996","journal-title":"Scand J Urol Nephrol"},{"key":"bib26-20230925","first-page":"355","article-title":"Management of biochemically recurrent prostate cancer: ensuring the right treatment of the right patient at the right time","volume":"38","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:08:28Z","timestamp":1695622108000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003122","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,26]]}}}